Antoine Papiernik, Author at Labiotech.eu

About

Antoine Papiernik is a Managing Partner at the life sciences VC firm Sofinnova Partners. He has been an initial investor and active board member in Actelion, ProQR, NovusPharma, Movetis, Mainstay, Pixium Vision and Stentys, among others.

Articles by Antoine Papiernik

Antoine Papiernik Sofinnova Partners life science

Opinion 14 Mar 2022

The Secrets to 50 Years of Success in Life Sciences Investment

The European life sciences venture capital firm Sofinnova Partners is celebrating its 50th birthday this year. Sofinnova’s Chairman and Managing Partner, Antoine Papiernik, outlines key lessons the company has learned in its long history in the biotech industry. Meet a couple who have been married for 50 years and most of us, I imagine, would […]

March 14, 2022 - 7 minutesmins - By Antoine Papiernik

Antoine Papiernik Sofinnova Partners Biotech Entrepreneurs

Opinion 7 Jul 2021

Three Lessons an Investor Can Learn from Biotech Entrepreneurs

Sofinnova Partners’ Chairman and Managing Partner, Antoine Papiernik, describes his company’s ‘Wall of Fame’ showcasing its entrepreneurs and how their years of experience provide a source of inspiration for venture capitalists. Every time I walk through our Paris office, I am greeted by a wall of photos showcasing some of the top entrepreneurial minds that […]

July 7, 2021 - 7 minutesmins - By Antoine Papiernik

Opinion 8 Mar 2021

Advice for my Younger Self: How to Be a VC in Life Sciences

Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, looks back at where he was two decades ago and shares what he would tell his younger self about being a life sciences VC. I am not a scientist or a doctor. Twenty years ago, when I was starting my career in this business, someone like […]

March 8, 2021 - 5 minutesmins - By Antoine Papiernik

Opinion 30 Sep 2019

Can European Biotech Companies Afford Not to Work with China?

In the current trade standoff between the US and China, Europe has a golden opportunity to gain a competitive advantage. At every healthcare conference I’ve been to recently in the US or Europe, the same question is being debated on panels: Should you or should you not have a China strategy as a biotech CEO? […]

September 30, 2019 - 4 minutesmins - By Antoine Papiernik

Opinion 16 Jul 2019

The Business of Biotech: What to Do When the S*#t Hits the Fan

From CEO-itis to FDA-itis, the path of a biotech company is never dull. Whether the oft-repeated saying, “may you live in interesting times,” is a blessing or a curse depends entirely on your perspective. As a life science venture capital investor with close to 25 years of experience, I have encountered many unexpected and interesting […]

July 16, 2019 - 5 minutesmins - By Antoine Papiernik

Opinion 5 Jun 2019

Is Going Public in Europe the Kiss of Death?

The key for a European biotech is to find the money where it is. And that’s not in Europe for the moment. Going public is obviously a necessary evil for any biotech company looking to become a self-standing entity taking its drugs to market. Doing so provides the funding, the public forum, and the governance […]

June 5, 2019 - 6 minutesmins - By Antoine Papiernik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us